One step forward: The use of transgenic zebrafish tumor model in drug screens

Birth Defects Research Part C - Embryo Today: Reviews

Volumn 93, Issue 2, 2011, Pages 173-181

  Huang, Xiaoqian ^a   Nguyen, Anh Tuan ^a   Li, Zhen ^a   Emelyanov, Alexander ^a   Parinov, Serguei ^a   Gong, Zhiyuan ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Drug screening; Liver cancer; Transgenic fish; Zebrafish

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANTINEOPLASTIC AGENT; CYCLOPAMINE; DOXYCYCLINE; INDIRUBIN; MIFEPRISTONE; SU 4312; UNCLASSIFIED DRUG;

AUTOMATION; CANCER MODEL; CANCER RESEARCH; DRUG EFFICACY; DRUG RESEARCH; DRUG SCREENING; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSGENIC ANIMAL; ZEBRA FISH;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; DRUG DISCOVERY; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; LIVER NEOPLASMS; MODELS, ANIMAL; SIGNAL TRANSDUCTION; ZEBRAFISH;

DANIO RERIO; VERTEBRATA;

EID: 79958847884     PISSN: 1542975X     EISSN: 15429768     Source Type: Journal    
DOI: 10.1002/bdrc.20208     Document Type: Review

References (70)

1. Amatruda JF, Shepard JL, Stern HM, Zon LI. 2002. Zebrafish as a cancer model system. Cancer Cell 1: 229-231.
2. Baker M. 2011. Screening: the age of fishes. Nat Methods 8: 47-51.
3. Berghmans S, Hunt J, Roach A, Goldsmith P. 2007. Zebrafish offer the potential for a primary screen to identify a wide variety of potential anticonvulsants. Epilepsy Res 75: 18-28.
4. Bowman TV, Zon LI. 2010. Swimming into the future of drug discovery: in vivo chemical screens in zebrafish. ACS Chem Biol 5: 159-161.
5. Chan J, Bayliss PE, Wood JM, Roberts TM. 2002. Dissection of angiogenic signaling in zebrafish using a chemical genetic approach. Cancer Cell 1: 257-267.
6. Chan JN, Nislow C, Emili A. 2010. Recent advances and method development for drug target identification. Trends Pharmacol Sci 31: 82-88.
7. Chen YH, Wang YH, Yu TH, et al. 2009. Transgenic zebrafish line with over-expression of Hedgehog on the skin: a useful tool to screen Hedgehog-inhibiting compounds. Transgenic Res 18: 855-864.
8. Chiu LL, Cunningham LL, Raible DW, et al. 2008. Using the zebrafish lateral line to screen for ototoxicity. JAssoc Res Otolaryngol 9: 178-190.
9. Choi TY, Kim JH, Ko DH, et al. 2007. Zebrafish as a new model for phenotype-based screening of melanogenic regulatory compounds. Pigment Cell Res 20: 120-127.
10. Gong ZY, Koh CHV, Nguyen AT, et al. 2010. The zebrafish model for liver carcinogenesis. In: Wang X, Grisham J, Thorgeirsson S, editors. Molecular genetics of liver neoplasia.1st ed. New York: Springer. pp. 197-217.
11. Goodman LS, Wintrobe MM, Dameshek W, et al. 1984. Nitrogen mustard therapy. Use of methyl-bis(beta-chloroethyl)amine hydrochloride and tris (beta-chloroethyl)amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. JAMA 251: 2255-2261.
12. Gossen M, Bujard H. 1992. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 89: 5547-5551.
13. Halpern ME, Rhee J, Goll MG, et al. 2008. Gal4/UAS transgenic tools and their application to zebrafish. Zebrafish 5: 97-110.
14. Hans S, Freudenreich D, Geffarth M, et al. 2011. Generation of a non-leaky heat shock-inducible Cre line for conditional Cre/lox strategies in zebrafish. Dev Dyn 240: 108-115.
15. Hans S, Scheer N, Riedl I, et al. 2004. her3, a zebrafish member of the hairy-E(spl) family, is repressed by Notch signalling. Development 131: 2957-2969.
16. Hawkins WE, Overstreet RM, Fournie JW, Walker WW. 1985. Development of aquarium fish models for environmental carcinogenesis: tumor induction in seven species. J Appl Toxicol 5: 261-264.
17. Her GM, Chiang CC, Chen WY, Wu JL. 2003. In vivo studies of liver-type fatty acid binding protein (L-FABP) gene expression in liver of transgenic zebrafish (Danio rerio). FEBS Lett 538: 125-133.
18. Hisaoka KK. 1958. The effects of 2-acetylaminofluorene on the embryonic development of the zebrafish. II. Histochemical studies. Cancer Res 18: 664-667.
19. Jagadeeswaran P, Liu YC. 1997. A hemophilia model in zebrafish: analysis of hemostasis. Blood Cells Mol Dis 23: 52-57.
20. Jeong JY, Einhorn Z, Mathur P, et al. 2007. Patterning the zebrafish diencephalon by the conserved zinc-finger protein Fezl. Development 134: 127-136.
21. Koster RW, Fraser SE. 2001. Tracing transgene expression in living zebrafish embryos. Dev Biol 233: 329-346.
22. Lam SH, Wu YL, Vega VB, et al. 2006. Conservation of gene expression signatures between zebrafish and human liver tumors and tumor progression. Nat Biotechnol 24: 73-75.
23. Langenau DM, Feng H, Berghmans S, et al. 2005. Cre/lox-regulated transgenic zebrafish model with conditional myc-induced T cell acute lymphoblastic leukemia. Proc Natl Acad Sci USA 102: 6068-6073.
24. Langenau DM, Jette C, Berghmans S, et al. 2005. Suppression of apoptosis by bcl-2 overexpression in lymphoid cells of transgenic zebrafish. Blood 105: 3278-3285.
25. Langenau DM, Keefe MD, Storer NY, et al. 2007. Effects of RAS on the genesis of embryonal rhabdomyosarcoma. Genes Dev 21: 1382-1395.
26. Langenau DM, Traver D, Ferrando AA, et al. 2003. Myc-induced T cell leukemia in transgenic zebrafish. Science 299: 887-890.
27. Lewis TJ. 2010. Toxicity and cytopathogenic properties toward human melanoma cells of activated cancer therapeutics in zebra fish. Integr Cancer Ther 9: 84-92.
28. Lord AM, North TE, Zon LI. 2007. Prostaglandin E2: making more of your marrow. Cell Cycle 6: 3054-3057.
29. Michelini E, Cevenini L, Mezzanotte L, et al. 2010. Cell-based assays: fuelling drug discovery. Anal Bioanal Chem 398: 227-238.
30. Murphey RD, Stern HM, Straub CT, Zon LI. 2006. A chemical genetic screen for cell cycle inhibitors in zebrafish embryos. Chem Biol Drug Des 68: 213-219.
31. Nicoli S, Presta M. 2007. The zebrafish/tumor xenograft angiogenesis assay. Nat Protoc 2: 2918-2923.
32. North TE, Goessling W, Walkley CR, et al. 2007. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature 447: 1007-1011.
33. Ou HC, Cunningham LL, Francis SP, et al. 2009. Identification of FDA-approved drugs and bioactives that protect hair cells in the zebrafish (Danio rerio) lateral line and mouse (Mus musculus) utricle. J Assoc Res Otolaryngol 10: 191-203.
34. Ou HC, Santos F, Raible DW, et al. 2010. Drug screening for hearing loss: using the zebrafish lateral line to screen for drugs that prevent and cause hearing loss. Drug Discov Today 15: 265-271.
35. Owens KN, Santos F, Roberts B, et al. 2008. Identification of genetic and chemical modulators of zebrafish mechanosensory hair cell death. PLoS Genet 4: e1000020.
36. Park SW, Davison JM, Rhee J, et al. 2008. Oncogenic KRAS induces progenitor cell expansion and malignant transformation in zebrafish exocrine pancreas. Gastroenterology 134: 2080-2090.
37. Patton EE, Widlund HR, Kutok JL, et al. 2005. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol 15: 249-254.
38. Peterson RT, Link BA, Dowling JE, Schreiber SL. 2000. Small molecule developmental screens reveal the logic and timing of vertebrate development. Proc Natl Acad Sci USA 97: 12965-12969.
39. Picard D, Salser SJ, Yamamoto KR. 1988. A movable and regulable inactivation function within the steroid binding domain of the glucocorticoid receptor. Cell 54: 1073-1080.
40. Pruvot B, Jacquel A, Droin N, et al. 2011. Leukemic cell xenograft in zebrafish embryo for investigating drug efficacy. Haematologica 96: 612-616.
41. Raghunath M, Sy Wong Y, Farooq M, Ge R. 2009. Pharmacologically induced angiogenesis in transgenic zebrafish. Biochem Biophys Res Commun 378: 766-771.
42. Rihel J, Prober DA, Arvanites A, et al. 2010. Zebrafish behavioral profiling links drugs to biological targets and rest/wake regulation. Science 327: 348-351.
43. Sadowski I, Ma J, Triezenberg S, Ptashne M. 1988. GAL4-VP16 is an unusually potent transcriptional activator. Nature 335: 563-564.
44. Santoriello C, Gennaro E, Anelli V, et al. 2010. Kita driven expression of oncogenic HRAS leads to early onset and highly penetrant melanoma in zebrafish. PLoS One 5: e15170.
45. Schartl M. 1990. Homology of melanoma-inducing loci in the genus Xiphophorus. Genetics 126: 1083-1091.
46. Scheer N, Campos-Ortega JA. 1999. Use of the Gal4-UAS technique for targeted gene expression in the zebrafish. Mech Dev 80: 153-158.
47. Scheer N, Groth A, Hans S, Campos-Ortega JA. 2001. An instructive function for Notch in promoting gliogenesis in the zebrafish retina. Development 128: 1099-1107.
48. Serbedzija GN, Flynn E, Willett CE. 1999. Zebrafish angiogenesis: a new model for drug screening. Angiogenesis 3: 353-359.
49. Shou WZ, Zhang J. 2010. Recent development in high-throughput bioanalytical support for in vitro ADMET profiling. Expert Opin Drug Metab Toxicol 6: 321-336.
50. Spitsbergen JM, Kent ML. 2003. The state of the art of the zebrafish model for toxicology and toxicologic pathology research-advantages and current limitations. Toxicol Pathol 31: 62-87.
51. Spitsbergen JM, Tsai HW, Reddy A, et al. 2000a. Neoplasia in zebrafish (Danio rerio) treated with 7, 12-dimethylbenz[a]anthracene by two exposure routes at different developmental stages. Toxicol Pathol 28: 705-715.
52. Spitsbergen JM, Tsai HW, Reddy A, et al. 2000b. Neoplasia in zebrafish (Danio rerio) treated with N-methyl-N′-nitro-N-nitrosoguanidine by three exposure routes at different developmental stages. Toxicol Pathol 28: 716-725.
53. Spitsbergen JM, Tsai HW, Reddy A, et al. 2000c. Neoplasia in zebrafish (Danio rerio) treated with N-methyl-N′-nitro-N-nitrosoguanidine by three exposure routes at different developmental stages. Toxicol Pathol 28: 716-725.
54. Sun L, Xu W, He J, Yin Z. 2010. In vivo alternative assessment of the chemicals that interfere with anterior pituitary POMC expression and interrenal steroidogenesis in POMC: EGFP transgenic zebrafish. Toxicol Appl Pharmacol 248: 217-225.
55. Ton C, Parng C. 2005. The use of zebrafish for assessing ototoxic and otoprotective agents. Hear Res 208: 79-88.
56. Tran TC, Sneed B, Haider J, et al. 2007. Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafish. Cancer Res 67: 11386-11392.
57. Ung CY, Lam SH, Gong Z. 2009. Comparative transcriptome analyses revealed conserved biological and transcription factor target modules between the zebrafish and human tumors. Zebrafish 6: 425-431.
58. Urlinger S, Baron U, Thellmann M, et al. 2000. Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc Natl Acad Sci USA 97: 7963-7968.
59. Van Leeuwen CJ, Grootelaar EM, Niebeek G. 1990. Fish embryos as teratogenicity screens: a comparison of embryotoxicity between fish and birds. Ecotoxicol Environ Saf 20: 42-52.
60. Walter RB, Kazianis S. 2001. Xiphophorus interspecies hybrids as genetic models of induced neoplasia. ILAR J 42: 299-321.
61. Wang C, Tao W, Wang Y, et al. 2010. Rosuvastatin, identified from a zebrafish chemical genetic screen for antiangiogenic compounds, suppresses the growth of prostate cancer. Eur Urol 58: 418-426.
62. Wang YH, Wen CC, Yang ZS, et al. 2009. Development of a whole-organism model to screen new compounds for sun protection. Mar Biotechnol (NY) 11: 419-429.
63. Weigelt J. 2009. The case for open-access chemical biology. A strategy for pre-competitive medicinal chemistry to promote drug discovery. EMBO Rep 10: 941-945.
64. Xiang J, Yang H, Che C, et al. 2009. Identifying tumor cell growth inhibitors by combinatorial chemistry and zebrafish assays. PLoS One 4: e4361.
65. Yang HW, Kutok JL, Lee NH, et al. 2004. Targeted expression of human MYCN selectively causes pancreatic neuroendocrine tumors in transgenic zebrafish. Cancer Res 64: 7256-7262.
66. Yu PB, Hong CC, Sachidanandan C, et al. 2008. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol 4: 33-41.
67. Zhang J, Sattler M, Tonon G, et al. 2009. Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma. Cancer Res 69: 5082-5090.
68. Zhong H, Lin S. 2011. Chemical screening with zebrafish embryos. Methods Mol Biol 716: 193-205.
69. Zhong H, Xin S, Zhao Y, et al. 2010. Genetic approach to evaluate specificity of small molecule drug candidates inhibiting PLK1 using zebrafish. Mol Biosyst 6: 1463-1468.
70. Zhong H, Zou H, Semenov MV, et al. 2009. Characterization and development of novel small-molecules inhibiting GSK3 and activating Wnt signaling. Mol Biosyst 5: 1356-1360.